Drug Profile
MDI 101
Latest Information Update: 30 Mar 2011
Price :
$50
*
At a glance
- Originator Molecular Design International
- Class Antiacnes; Antipsoriatics; Keratolytics; Retinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acne; Photodamage; Psoriasis
Most Recent Events
- 30 Mar 2011 Discontinued - Phase-I for Acne in USA (Topical)
- 30 Mar 2011 Discontinued - Preclinical for Photodamage in USA (Topical)
- 30 Mar 2011 Discontinued - Preclinical for Psoriasis in USA (Topical)